Home Tags CGMP

Tag: cGMP

On October 16, 2019 Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and WuXi Biologics signed a strategic partnership for Phase III clinical trial production of ARX788 as well ongoing large-scale commercial production of the innovative antibody-drug conjugate.

WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing

Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good Manufacturing Practice (cGMP)-approved DP3 bulk...

WuXi Biologics Starts Construction of a State-of-the-Art R&D and Manufacturing Center...

WuXi Biologics, a Hong Kong-listed, open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has started the construction of...

Promising Preclinical Results Show Antibody Effectively Targets CD74 in Lymphoma and...

Two studies presented at the annual meeting of the American Society of Hematology (ASH), held December 9 - 12, 2017, showed frequent expression of...

Evolving CMC Analytical Techniques for Biopharmaceuticals

1.0 Abstract During the (early) preclinical drug development process as well as manufacturing of biopharmaceutical (protein) products, analysis and characterization are crucial in gaining a...

When Data Integrity Takes Center Stage

1.0 Abstract Data integrity has become an important issue. To comply with regulations, companies need to optimize data integrity and the underlying strategies involved in...

The Challenge of cGMP in the Manufacturing of Antibody-drug Conjugates

1.0 Introduction Antibody-drug Conjugates or ADCs are a new generation of highly hazardous / highly toxic pharmaceutical products used, among other things, in the targeted...